健康受试者中缓释氯胺酮片的手性药代动力学及代谢物特征
该研究在15名健康白人受试者中开展剂量递增试验,比较静脉输注5.0 mg氯胺酮与单次口服10、20、40、80 mg缓释片后的手性药代动力学。结果显示40 mg缓释片后2,6-羟基去甲氯胺酮/氯胺酮AUC比值显著高于静脉输注,提示缓释片可产生更高的2,6-羟基去甲氯胺酮全身暴露。
要点
- 缓释氯胺酮片使2,6-羟基去甲氯胺酮相对氯胺酮的暴露显著高于静脉输注。
- 40 mg缓释片生物利用度S-异构体15±8%、R-异构体19±10%。
- 缓释片终末半衰期S-异构体11±4 h、R-异构体10±4 h。
核心结论
- 缓释氯胺酮片可产生高的2,6-羟基去甲氯胺酮全身暴露,可能成为治疗慢性神经病理性疼痛更有效且更安全的剂型。
研究设计与样本
- 在15名健康白人受试者中进行的对照、剂量递增药代动力学研究,比较静脉输注5.0 mg与单次口服10、20、40、80 mg缓释片。
主要发现
- 40 mg缓释片后2,6-羟基去甲氯胺酮/氯胺酮AUC比值S-异构体为18±11、R-异构体为30±16,静脉输注后分别为1.7±0.8和3.1±1.4(均P<0.001)。
- 10和20 mg片剂后R-异构体比值更高。
- S-和R-氯胺酮稳态分布容积分别为6.6±2.2和5.6±2.1 l/kg,终末半衰期分别为5.2±3.4和6.1±3.1 h,代谢清除率分别为1,620±380和1,530±380 ml/min。
- 40 mg片剂生物利用度S-异构体15±8%、R-异构体19±10%,终末半衰期分别为11±4和10±4 h。
- 约7%剂量以S-异构体、17%以R-异构体经肾排泄。
临床怎么用
- 缓释氯胺酮片可能用于慢性神经病理性疼痛的治疗,其2,6-羟基去甲氯胺酮暴露高于静脉输注。
局限性
- 研究在15名健康白人受试者中进行,样本量小且人群单一。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The anesthetic ketamine after intravenous dosing is nearly completely metabolized to R- and S-stereoisomers of the active norketamine (analgesic, psychoactive) and 2,6-hydroxynorketamine (potential analgesic, antidepressant) as well as the inactive dehydronorketamine. Oral administration favors the formation of 2,6-hydroxynorketamines via extensive presystemic metabolism. The authors hypothesized that plasma exposure to 2,6-hydroxynorketamines relative to the psychoactive ketamine is greater after prolonged-release ketamine tablets than it is after intravenous ketamine. METHODS: Pharmacokinetics of ketamine after intravenous infusion (5.0 mg) and single-dose administrations of 10, 20, 40, and 80 mg prolonged-released tablets were evaluated in 15 healthy white human subjects by means of a controlled, ascending-dose study. The stereoisomers of ketamine and metabolites were quantified in serum and urine by validated tandem mass-spectrometric assays and evaluated by noncompartmental pharmacokinetic analysis. RESULTS: After 40 mg prolonged-release tablets, the mean ± SD area under the concentrations-time curve ratios for 2,6-hydroxynorketamine/ketamine were 18 ± 11 (S-stereoisomers) and 30 ± 16 (R-stereoisomers) compared to 1.7 ± 0.8 and 3.1 ± 1.4 and after intravenous infusion (both P < 0.001). After 10 and 20 mg tablets, the R-ratios were even greater. The distribution volumes at steady state of S- and R-ketamine were 6.6 ± 2.2 and 5.6 ± 2.1 l/kg, terminal half-lives 5.2 ± 3.4 and 6.1 ± 3.1 h, and metabolic clearances 1,620 ± 380 and 1,530 ± 380 ml/min, respectively. Bioavailability of the 40 mg tablets was 15 ± 8 (S-isomer) and 19 ± 10% (R-isomer) and terminal half-life 11 ± 4 and 10 ± 4 h. About 7% of the dose was renally excreted as S-stereoisomers and 17% as R-stereoisomers. CONCLUSIONS: Prolonged-release ketamine tablets generate a high systemic exposure to 2,6-hydroxynorketamines and might therefore be an efficient and safer pharmaceutical dosage form for treatment of patients with chronic neuropathic pain compared to intravenous infusion.
引用
- Hasan M, Modess C, Roustom T, et al. Chiral Pharmacokinetics and Metabolite Profile of Prolonged-release Ketamine Tablets in Healthy Human Subjects. Anesthesiology. 2021. PMID: 34019627. doi:10.1097/ALN.0000000000003829
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。